前列腺癌根治术后瘤床复发MRI图谱:七种勾画指南一致性评估
结果显示ESTRO和PERYTON定义的覆盖最高,EORTC覆盖显著较低,提示前者更适用于挽救放疗靶区勾画。
要点
- 病灶最常见于膀胱尿道吻合口(53%)、膀胱颈(29%)和膀胱后区(18%)。
- 基于质心的覆盖率ESTRO、PMH和PERYTON最高(92.1%-92.9%),EORTC显著较低。
- 作者基于覆盖标准支持ESTRO和PERYTON定义用于前列腺窝勾画。
核心结论
- 基于覆盖标准,研究数据支持使用ESTRO和PERYTON定义勾画前列腺窝临床靶区。
- 基于MRI的瘤床复发图谱可帮助优化挽救放疗勾画。
研究设计与样本
- 在T2加权MRI上勾画病灶,经形变配准转移至参考数据集生成三维复发发生率图。
- 在参考数据集上实施七种前列腺窝临床靶区勾画策略并比较覆盖。
主要发现
- 病灶位于膀胱尿道吻合口53%、膀胱颈29%、膀胱后区18%。
- 病灶中位体积:膀胱尿道吻合口0.48 cm³(范围0.03-40.5 cm³),膀胱后区0.29 cm³(范围0.09-3.72 cm³),膀胱颈0.49 cm³(范围0.02-3.51 cm³)。
- 基于质心的覆盖率为65%-93%,ESTRO、PMH和PERYTON最高(92.1%-92.9%)。
- 基于体积的覆盖率为63.7%-91.2%,ESTRO为91.2%、PERYTON为90.3%。
- EORTC策略在多数比较中覆盖显著低于其他策略,PMH与RTOG相关性最高(ρ=0.94)。
关键数值与推荐
- 基于质心覆盖率ESTRO、PMH和PERYTON为92.1%-92.9%,EORTC为65%。
- 基于体积覆盖率ESTRO为91.2%、PERYTON为90.3%,EORTC为63.7%。
临床怎么用
- 勾画前列腺窝临床靶区时可优先参考ESTRO或PERYTON定义以提高复发灶覆盖。
- 可结合本MRI复发图谱辅助识别膀胱尿道吻合口、膀胱颈和膀胱后区高危区域。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To create a magnetic resonance image (MRI)-based atlas of prostate bed recurrence for prostate cancer patients undergoing salvage radiation therapy (sRT) after radical prostatectomy, and to evaluate the consistency of contouring guidelines for the prostatic fossa-clinical target volume. METHODS AND MATERIALS: Patients with biochemical recurrence and MRI-detected prostate bed lesions before sRT were included. Each lesion was contoured on T2-weighted (T2w) MRI using dynamic contrast-enhanced sequences for guidance. Lesions were transferred to a reference T2-w data set through deformable co-registration to generate a 3-dimensional recurrence incidence map. The volume and location of the lesions were extracted. Seven prostatic fossa-clinical target volume contouring strategies were implemented on the reference T2w data set to assess coverage: the European Organisation for Research and Treatment of Cancer, the Faculty of Radiation Oncology Genito-Urinary Group, the Francophone Group of Urological Radiotherapy, the Radiation Therapy Oncology Group, the Princess Margaret Hospital (PMH), the European Society for Radiotherapy and Oncology-Advisory Committee for Radiation Oncology Practice (ESTRO), and PERYTON. Centroid- and volume-based coverage rates were calculated, and statistical comparisons were performed using Cochran's Q or Friedman tests. Correlations were analyzed with phi or Spearman's (rho, ρ) coefficients. RESULTS: One hundred and thirty-one patients with 140 recurrences were identified. Lesions were located at the vesicourethral anastomosis (53%), bladder neck (29%), and retrovesical region (18%). Median volume of the lesion was 0.48 cm3 (range, 0.03-40.5 cm3) (vesicourethral anastomosis), 0.29 cm3 (range, 0.09-3.72 cm3) (retrovesical region), and 0.49 cm3 (range, 0.02-3.51 cm3) (bladder neck). Centroid-based coverage ranged from 65% to 93%, with ESTRO, PMH, and PERYTON achieving the highest rates (92.1%-92.9%). Volume-based coverage ranged from 63.7% to 91.2%, again favoring ESTRO (91.2%) and PERYTON (90.3%). The European Organisation for Research and Treatment of Cancer strategy showed significantly lower coverage than all other contouring strategies in most comparisons, while strong positive correlations were observed among the remaining definitions, with the highest correlation between PMH and the Radiation Therapy Oncology Group (ρ = 0.94). CONCLUSIONS: According to the coverage criterion, our data support the use of ESTRO and PERYTON definitions. Here, we provide an MRI-based atlas of prostatic bed recurrence that can help optimize sRT contours.
引用
- Bottero M, Marzi S, Avanzolini I, et al. Magnetic Resonance Imaging-Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Consistency of Clinical Target Volume Delineation With Seven Contouring Guidelines. Pract Radiat Oncol. 2026. PMID: 42144102. doi:10.1016/j.prro.2026.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。